Inhibikase Therapeutics (IKT) Invested Capital (2022 - 2025)
Inhibikase Therapeutics' (IKT) quarterly Invested Capital came in at $37944.0 in Q2 2025, down 75.07% year-on-year from $152224.0 in Q2 2024, and down 49.25% on a QoQ basis from $74772.0 in Q1 2025.
Inhibikase Therapeutics (IKT) Invested Capital (2022 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of Invested Capital data on file, last reported at $37944.0 in Q2 2025.
- On a quarterly basis, Invested Capital fell 75.07% year-over-year to $37944.0 in Q2 2025; TTM through Mar 2026 was $37944.0, a 92.14% decrease from a year earlier, with the FY2024 full-year figure at $110517.0, down 26.37% from the prior year.
- Invested Capital for Q2 2025 stood at $37944.0, down from $74772.0 in the prior quarter.
- Over the last five years, Invested Capital for IKT reached as high as $152224.0 in Q2 2024 and fell as low as $37944.0 in Q2 2025.
- Historically, Invested Capital has averaged $129475.2 across 4 years, with a median of $146368.5 in 2022.
- Across the five-year window, Invested Capital gained 4.92% in 2023 and sank 75.07% in 2025, its largest moves.
- Year by year, Invested Capital stood at $145836.0 in 2022, then rose by 2.92% to $150095.0 in 2023, then slipped by 26.37% to $110517.0 in 2024, then plunged by 65.67% to $37944.0 in 2025.
- Per Business Quant data, the three most recent Invested Capital figures were $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.96 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 116.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 37,944.00 |
| Mar 31, 2025 | 74,772.00 |
| Dec 31, 2024 | 110,517.00 |
| Sep 30, 2024 | 145,210.00 |
| Jun 30, 2024 | 152,224.00 |
| Mar 31, 2024 | 151,159.00 |
| Dec 31, 2023 | 150,095.00 |
| Sep 30, 2023 | 149,030.00 |
| Jun 30, 2023 | 147,966.00 |
| Mar 31, 2023 | 146,901.00 |
| Dec 31, 2022 | 145,836.00 |
| Sep 30, 2022 | 142,048.00 |